title: Conversion from cyclosporine to tacrolimus improves renal function and lipid profile after cardiac transplantation.
abstract: BACKGROUND
  Calcineurin inhibitors (CNIs) have become the cornerstone of immunosuppressive regimens following heart transplantation, but their use is associated with nephrotoxicity. The impact on renal function after conversion from cyclosporine (CsA) to tacrolimus (TAC) is reported.
  
  
  METHODS
  Fifteen patients (men age 42 +/- 11 years) after cardiac transplantation (HTX) were switched from CsA to TAC (mean time after HTX 21 +/- 6 months). There were 13 male and 2 female patients. Mean cholesterol and LDL level at the time of conversion were 217 +/- 65 ml/dl and and 136 +/- 51 mg/100 ml respectively. Indication for HTX was ischemic cardiomyopathy (CMP) in 8, congenital in 3 and dilatative CMP in the remaining 4 patients.
  
  
  RESULTS
  Mean tacrolimus level (microg/dl) at 1, 3, 6 and 12 months were 8.6 +/- 3.3, 8.6 +/- 1.4, 9.2 +/- 2.8 and 9.8 +/- 2.5 respectively. There was a statistically significant improvement in creatinine levels at 1, 3, 6 and 12 months after conversion from baseline 1.9 +/- 0.7 mg/dl to 1.4 +/- 0.5 mg/dl, 1.4 +/- 0.4 mg/dl, 1.3 +/- 0.4 mg/dl and 1.2 +/- 0.4 mg/dl, respectively (p < 0.05). Furthermore, TAC decreased cholesterol as well as LDL-levels during this one-year time frame.
  
  
  CONCLUSIONS
  This study shows that conversion from CsA to tacrolimus after orthotopic heart transplantation improves renal function.
authors.affiliation: Department of Cardiothoracic Surgery, CSKMWiA, Poland. miroslaw.garlicki@cskmswia.pl
authors.forename: Mirosław
authors.initials: M
authors.lastname: Garlicki
authors.forename: Paweł
authors.initials: P
authors.lastname: Czub
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Labuś
authors.forename: Marek P
authors.initials: MP
authors.lastname: Ehrlich
authors.forename: Hanna
authors.initials: H
authors.lastname: Rdzanek
mesh_terms: D000328:Adult; D001794:Blood Pressure / Q000187:drug effects; D003404:Creatinine / Q000097:blood; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D016027:Heart Transplantation / Q000276:immunology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007677:Kidney Function Tests; D008055:Lipids / Q000097:blood*; D008297:Male; D012189:Retrospective Studies; D016559:Tacrolimus / Q000627:therapeutic use*; D013997:Time Factors
chemical_list: D007166:Immunosuppressive Agents; D008055:Lipids; D016572:Cyclosporine; D003404:Creatinine; D016559:Tacrolimus